Valeant Pharma (VRX) Reports Q2 Loss of $0.11, Adj-EBITDA Beats; Maintains FY EPS, Lowers FY Revs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Valeant Announces Second-Quarter 2017 Results
August 8, 2017 7:00 AM EDTLAVAL, Quebec, Aug. 8, 2017 /PRNewswire/ --
Second-Quarter 2017 Financial Results Revenues of $2.233 Billion GAAP Net Loss of $38 Million Adjusted Net Income (non-GAAP) of $362 Million Year-to-Date GAAP Cash Flow from Operations of $1.222 Billion Adjusted EBITDA (non-GAAP) Sequential Increase of 10% to $951 Million Delivered Strong Organic Growth1Â (non-GAAP) in Bausch + Lomb/International Segment and Salix Business Expects to Exceed $5 Billion Debt Reduction Commitment Early Updates 2017 Full-Year Revenue Guidance Range and Maintains 2017 Full-Year Adjusted EBITDA (non-GAAP)... More